Patients who choose depression treatment do better
Posted on: Tuesday, 20 September 2005, 16:55 CDT
NEW YORK (Reuters Health) - Allowing depressed patients to select their own treatment -- drug therapy, counseling or a combination of both -- may improve outcomes, researchers in Seattle report.
The findings are based on a study of 335 adult with a clinical diagnosis of depression. The subjects were surveyed regarding their preferred therapy and this was compared with the actual treatment received.
Dr. Susan C. Hedrick, from the VA Puget Sound Healthcare System, and colleagues, conducted telephone interviews to assess changes in functional status, severity of depression, disability, and other health outcomes at 1 week, 3 months, and 9 months.
Fifteen percent of patients preferred medication alone and these subjects were older and more likely to be white and married compared with the 24 percent who preferred just counseling or the 60 percent who preferred both, the report indicates.
Overall, 72 percent of the subjects received treatment that matched their preference, the investigators report in the Annals of Behavioral Medicine.
Although depression symptoms improved among patients in both groups, those who received a preferred treatment experienced more rapid improvements than those who received a therapy not matching their preference.
Co-author Dr. Edmund F. Chaney said in a statement: "The positive impact of treatment was more noticeable in the early stages of treatment. Although we can't say for certain, it might be that the preference-matched patients were better able to stick with the treatment plan in the early stages."
SOURCE: Annals of Behavioral Medicine, October 2005.
Source: REUTERS
Related Articles
- Astonishing 52 Percent of Newly Diagnosed Bipolar Disorder Patients Receive Antidepressant Drugs in First-Line Treatment
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
- New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)
- Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
- Cancer Patient Receives First Proton Therapy Treatment at University of Florida Proton Therapy Institute
- First Patient Receives Targeted Renal Therapy With FlowMedica's Benephit(TM) Delta Infusion System
- Trasylol(R) (Aprotinin Injection) Reduced Bleeding in Patients Receiving Anti-Platelet Therapy Prior to Coronary Artery Bypass Graft Surgery
- Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients
- Richland Firm Introduces Promising Isotope for Cancer Treatment; Prostate Cancer Patient Receives New Seed Therapy By IsoRay Medical, Inc. In a Worldwide First for Cesium-131
 |
 |
User Comments (0)
RSS Feeds